R.N. Safin1, R.Sh. Khasanov2, A.M. Gimranov1, S.V. Petrov1,3
1Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan
2Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
3Kazan State Medical University, Kazan
Safin Rustem N. ― oncologist, head of chemotherapy department №1 of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal
29 Sibirskiy trakt, Kazan, 420029, Russian Federation, tel. +7-917-272-79-93, e-mail: rustem1408@mail.ru, ORCID ID: 0000-0003-0585-7727
Abstract. Breast cancer diagnosis sets itself the tasks of disease staging and morphological verification, and includes non-invasive and invasive examination methods. The results obtained during the examination allow us to form a personalized treatment plan for each patient. Treatment of breast cancer, currently, is combined or complex. Neoadjuvant drug therapy is performed for locally common, both primary inoperable and operable forms of breast cancer, as well as for metastatic forms of breast cancer. Evaluation of the effectiveness of the treatment is carried out in the process of neoadjuvant therapy using non-invasive diagnostic methods and with pathomorphological examination of the drug removed during surgery. Achieving a complete pathomorphological response to neoadjuvant therapy can significantly improve the survival of patients with Her2-positive breast cancer. The article analyzes the results of observation of 19 patients with breast cancer who received combined treatment in Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal from 2021 to 2022. The effectiveness of the treatment was evaluated at all its stages, including neoadjuvate drug therapy, surgical treatment, adjuvate drug and radiation therapy.
Key words: Her2-positive breast cancer, neoadjuvant chemotherapy, ultrasound examination, pathomorphological response.